Although STAT inhibitors, alone or in combination with other drugs, have achieved promising effects, no STAT3 inhibitor has been approved for the treatment of lung cancer, likely due to their low bioavailability and off-target toxicities. This evidence concerns the gene STAT3 and lung cancer.